PUBLICERAT:
2015-05-14, kl: 03:42
"Getty Images Choosing a sunscreen used to be a numbers game: You’d go for a relatively high SPF (at least 30!) and slather it on. Turns out, there’s a lot more to consider to keep your skin safe from the sun and looking young, too. “What you really need to focus on is tailoring the kind of sunscreen to what you’re doing outdoors,” says Joshua Zeichner, MD, director of cosmetic and clinical research in dermatology at Mount Sinai Hospital in New York City. “If you’re not choosing your product ..."
PUBLICERAT:
2015-05-13, kl: 17:15
"... klinikens hudspecialist. Kerstin och en person till är de enda hudspecialisterna i Skandinavien om innehar europeisk specialistexamen, Diplomate of European College of Veterinary Dermatology (Dipl ECVD). Övriga må vara duktiga, men dessa två är proffs ..."
PUBLICERAT:
2015-04-14, kl: 17:10
"är en av de få hudvårdsmärkena i världen som fått sin studie runt QAL-100 patentet publicerad i en vetenskaplig tidskrift, närmare bestämt i British Journal of Dermatology och detta redan 2003. Studien leddes av hudläkaren Claes Britton som var närvarande ..."
PUBLICERAT:
2015-04-08, kl: 05:16
"Dr. Reddy’s Laboratories (NYSE:RDY) and its subsidiary, Promius PharmaTM, LLC today announced the filing of three 505(b)(2) New Drug Applications (NDAs) with the U.S. Food and Drug Administration (US FDA). The three NDAs – DFD-01, DFD-09, and DFN-11, are in support of Dr. Reddy’s Proprietary Products group, focused on developing and commercializing therapies in dermatology […] ..."
PUBLICERAT:
2015-03-20, kl: 18:01
"Celgene Corporation (NASDAQ: CELG) today announced that results from long-term efficacy and safety analyses of the ESTEEM phase III clinical trial program of Otezla(R) (apremilast) were presented at the 73rd Annual Meeting of the American Academy of Dermatology (AAD) in San Francisco, California. OTEZLA is the Company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4) approved […] ..."
PUBLICERAT:
2015-03-20, kl: 18:01
"Celgene Corporation (NASDAQ:CELG) today announced that results from its ongoing phase III LIBERATE trial evaluating Otezla(R) (apremilast), the Company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4), in patients with moderate to severe plaque psoriasis were presented at a late-breaker presentation at the 73rd Annual Meeting of the American Academy of Dermatology (AAD) in San Francisco, […] ..."
PUBLICERAT:
2015-03-20, kl: 18:01
"Pfizer Inc. (NYSE:PFE) announced today the presentation of detailed pooled results from two pivotal Phase 3 studies from the Oral treatment Psoriasis Trials (OPT) program at the 73rd American Academy of Dermatology (AAD) Annual Meeting. These results, evaluating the efficacy and safety of tofacitinib citrate for the treatment of adults with moderate to severe chronic […] ..."
PUBLICERAT:
2015-03-17, kl: 17:37
"... i Skandinavien om innehar europeisk specialistexamen, Diplomate of European College of Veterinary Dermatology (Dipl ECVD). Det säger väl inte så mycket, men allt jag har hört om henne är väldigt positivt. Vi har givetvis träffat specialister på hud ..."
PUBLICERAT:
2015-02-11, kl: 07:28
"Jo, jag läst det på EWG. För den som vill läsa så är det bara att slå på Retinyl Palmitate i EWG databas. De skiver ut namn men inga riktig referenser eller årtal så man vet inte när undersökningen gjordes. Sen läste jag bl.a. detta; Retinyl palmitate has been shown in UVB exposure studies to offer sun protection all by itself, and it is a potent antioxidant (Sources: International Journal of Pharmaceutics, October 2007, pages 181–189; and Journal of Investigative Dermatology, November 2003 ..."
PUBLICERAT:
2015-01-25, kl: 03:03
"6 billion Euros. With such a money in play, it is no wonder that Galderma is the sponsor of skin-cancer organisations around the world and that those organisations (like the “ Dermatology Foundation ” in the USA) are the sponsors of campaigns ..."